Show Stocks and Investing Publications • Thu, November 3, 2022
David Lebowitz Maintained (ASND) at Strong Buy with Increased Target to $163 on, Nov 3rd, 2022
ntained-asnd-at-strong-buy-with-increased-target-to-163-on-nov-3rd-2022.html
Stocks and Investing on Sun, Oct 27th, 2024David Lebowitz of Citigroup, Maintained "Ascendis Pharma A/S" (ASND) at Strong Buy with Increased Target from $157 to $163 on, Nov 3rd, 2022.
David has made no other calls on ASND in the last 4 months.
There are 5 other peers that have a rating on ASND. Out of the 5 peers that are also analyzing ASND, 0 agree with David's Rating of Hold.
These are the ratings of the 5 analyists that currently disagree with David
- Paul Choi of "Goldman Sachs" Initiated at Strong Buy and Held Target at $174 on, Thursday, October 20th, 2022
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $172 on, Thursday, September 22nd, 2022
- Caroline Palomeque of "Berenberg" Initiated at Strong Buy and Held Target at $166 on, Tuesday, August 30th, 2022
- Joseph Schwartz of "SVB Leerink" Maintained at Buy with Decreased Target to $168 on, Thursday, August 11th, 2022
- Leland Gershell of "Oppenheimer" Maintained at Buy with Decreased Target to $144 on, Thursday, August 11th, 2022